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Each candidate probiotic strain has to have the documentation for the proper identification with 
current molecular tools, for the biological properties, for the safety aspects and for the health 
benefits in human trials if the intention is to apply the strain as health promoting culture in the 
commercial applications. No generalization based on species properties of an existing probiotic 
are valid for any novel strain, as strain specific differences appear e.g. in the resistance to GI 
tract conditions and in health promoting benefits (Madsen, 2006). The strain evaluation based 
on individual strain specific probiotic characteristic  is therefore the first key action for the 
selection of the new probiotic candidate. 
 
The ultimate goal in the selection of the probiotic strain is to provide adequate amounts of 
active, living cells for the application and to guarantee that the cells are physiologically strong 
enough to survive and be biologically active in theadverse environmental conditions in the 
product and in GI tract of the host. The in vivo intervention studies are expensive and time 
consuming; therefore it is not rational to test all the possible candidates in vivo. Thus, the proper 
in vitro studies are helping to eliminate strains which are unlikely to perform well in vivo. 
 
The aims of this study were to characterize the strains of Propionibacterium freudenreichii ssp. 
shermanii JS and Lactobacillus rhamnosus LC705, both used for decades as cheese starter 
cultures, for their technological and possible probiotic functionality applied in a combined 
culture. The in vitro studies of Propionibacterium freudenreichii ssp. shermanii JS focused on 
the monitoring of the viability rates during the acid and bile treatments and on the safety aspects 
such as antibiotic susceptibility and adhesion. Thestudies with the combination of the strains JS 
and LC705 administered in fruit juices monitored the survival of the strains JS and LC705 
during the GI transit and their effect on gut wellbing properties measured as relief of 
constipation. In addition, safety parameters such as side effects and some peripheral immune 
parameters were assessed. Separately, the combination of P. freudenreichii ssp. shermanii JS 
and Lactobacillus rhamnosus LC705 was evaluated from the technological point of view as a 
bioprotective culture in fermented foods and wheat bread applications. 
 
In this study, the role of P. freudenreichii ssp. shermanii JS as a candidate probiotic culture 
alone and in a combination with L. rhamnosus LC705 was demonstrated. Both strains were 
transiently recovered in high numbers in fecal samples of healthy adults during the consumption 
period. The good survival through the GI transit was proven for both strains with a recovery rate 
from 70 to 80% for the JS strain and from 40 to 60% for the LC705 strain from the daily dose of 
10 log10 CFU. The good survival was shown from the consumption of fruit juices which do not 
provide similar matrix protection for the cells as milk based products. The strain JS did not pose 
any obvious safety concerns in vitro and no harmful side effects were reported in vivo by 
healthy adults or by institutionalized elderly during the consumption of the combination of the 
JS and LC705 strains. A decreasing frequency in level of IgA secreting cells (p=0.02) was 
reported in the healthy adults; however this change may not be biologically relevant. A relief of 
constipation (from 2.1 to 2.6 times/week; p=0.04) was reported in the institutionalized elderly 
and a slight, but insignificant tendency of increased defecation frequency was observed in 
healthy adults. The bioprotective antimicrobial role against yeasts and molds in fermented foods 
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1. REVIEW OF THE LITERATURE 
 
1.1. Introduction: from dairy starters to candidate probiotic cultures 
 
Propionic acid bacteria (PAB) have been used for deca s for technological applications in the 
food industry.  
  
The original aims in applying lactic and propionic a id bacteria in foods was as technological 
starters for improving the shelf life, texture and flavour of the products. The new era for these 
bacteria was raised at time when Metchnikoff published his early findings of beneficial effects of 
Lactobacillus sp. as probiotics (from Greek words “for life”), and currently probiotics are 
becoming increasingly important in the context of human nutrition and wellbeing. Scientific 
evidence accumulates in rebalancing the disrupted gastrointestinal (GI) –tract and in alleviating 
infectious disease especially in children (reviewed by Walker et al., 2006; Pham et al., 2008). In 
particular, certain strains belonging to Bifidobacteria and Lactobacillus species are the most 
widely studied and exploited probiotics. Of the dairy propionibacteria, species P. acidipropionici 
and P. freudenreichii are introduced as possible candidate probiotics (Mantere-Alhonen, 1995; 
Bougle et al., 1999; Jan et al., 2002, Ouwehand, 2004). 
 
Interest in various types of food products and dietary supplements with probiotic bacteria is 
continuously expanding. Fermented foods and dairy products are by far the most popular human 
applications for probiotics due to traditionally known positive health image of fermented foods 
and, on the other hand, due to the fact that consumers are familiar with these products containing 
living microorganisms (Heller, 2001). Additionally, dairy products are excellent matrixes for the 
delivery of probiotics because of the buffering capacity of the milk (Salminen & Playne, 2001) 
and milk fats (Stanton et al., 1998) against acid secretions in the upper gastrointestinal tract. In 
parallel with growing consumer awareness on the benefits of probiotics, interest in 
supplementing other food products than fermented dairy products with the probiotics is one of the 
current issues in research and product development. The latest innovation in probiotic products 
with a market volume of more than 1000 million kg, is the daily-dose drinks in small bottle 
(Buss, 2004). Other novel food applications are e.g. infant foods, non-dairy foods, soft drinks and 
dietary supplements (for review, see Champagne et al., 2005).  
 
The probiotic strains are challenged in food or supplement applications by different stresses 
during the production and in the gastrointestinal tr ct as illustrated in Table 1 (modification from 
Lacroix & Yildrim, 2007) and therefore the basis for the strain selection is the strain’s ability to 
adapt to different stresses during production and during the transit in the intestine. The ultimate 
goal in the selection of the strains is to provide a quate amounts of active, living probiotic cells 
for the application and to guarantee that the cells are physiologically strong enough for the 
environmental conditions in the product and especially in GI tract of the host. The strain selection 






Table 1.  Main factors affecting the viability of probiotics from production to the gastrointestinal 
tract (modified after Lacroix & Yildirim, 2007) 
 
Steps from production to gastrointestinal tract 
Fermentation Downstream 
process 
Storage Gastrointestinal tract 
Composition of 
growth medium 










during spray or 
freeze drying 
Competition with 




Final cell mass Cell dehydration Temperature Bile salts in the small 
intestine 





1.2.1. Definition  
 
Since the first definition of probiotics as “micro-organisms stimulating the growth of another” by 
Lilly and Stillwell (1965) the term has been redefin d several times from the initial improvement 
in intestinal microbiota to the health effects outside the intestine (Salminen et al.1998; 
Schrezenmeier and de Vrese, 2001). The latest definition is given by FAO/WHO expert panel as 
“ live micro-organisms which, when consumed in adequate amounts, confer a health benefit 
on the host” (Food and Agriculture Organization & World Health Organization, 2002). At 
present, scientific evidence is sufficient for indicating the potential of probiotic foods with well 
characterized strains to provide health benefits and that those specific strains are safe for human 
consumption (FAO/WHO, 2002). It is noteworthy that different strains may have different effects 
to humans and therefore the current concept of the probiotics states that the beneficial effects are 
based on the specificity of the clearly defined strain, applied either as a monoculture or as a part 
in a multistrain mixture. 
 
1.2.2. Current probiotic strains and their clinical use 
 
The microbes mostly studied and currently used as probiotics are specific strains belonging 
mainly to Lactobacillus or Bifidobacterium species. The interests in studying these species as 
probiotic are based on their association with healty human tract (Boyle et.al., 2006) and on their 





number of probiotic strains studied and claimed to have probiotic activity is high, but only a 
handful of species dominate the market (Table 2). 
 
Table 2. The main probiotic strains applied commercially in the EU member states  
 
 Supplier Commercial brand 
name(s) 
Bifidobacterium animalis sp. 
lactis BB-12 
Chr.Hansen A/S Several brands 
B. lactis HNO19 Danisco Howaru™ Bifido 
B. animalis ssp. animalis DN 
173 010 




Danone Lactobacillus Defensis; 
Actimel 
L .rhamnosus HN001 Danisco Howaru™ Rhamnosus 
L. casei shirota  Yakult 
L. plantarum 299v Probi AB Proviva 
L. reuterii ATTC 55730 Arla-Ingman RELA 
L. rhamnosus GG ATTC 53013  Valio Ltd Gefilus; LGG, Vifit; 
Cultura, Actifit, etc. 
 
The positive effects in treating gastrointestinal disorders, especially in the incidence or duration 
of rotavirus diarrhea in children are well evidenced by placebo-controlled intervention trials (de 
Vrese & Marteau, 2001; Gill & Guarner, 2004). Based on meta-analysis of Cochrane reviews 
(Allen et al., 2004) and D’Souza et al. (2002), sufficient evidence exists to recommend the use of 
L.rhamnosus LGG in milk or in capsules as an adjunct to oral rehydration therapy for the 
treatment of rotavirus diarrhea. Also, well documented evidence is supporting the balancing role 
of probiotics during antibiotic treatments both in children (Johnston et al., 2006) and in adults 
(Cremonini et al., 2002; Engelbrektson et al., 2009). Putative, positive indications exist for the 
management of inflammatory bowel syndrome (IBS) (Kajander et al., 2005; 2008) which is a 
functional bowel disorder. In case of ulcerative colitis which is one of the different forms of 
inflammatory bowel disease (IBD), probiotics may provide modest benefits in mild to moderately 
severe ulcerative colitis, but the evidence is limited (Mallon et al., 2007). 
 
Probiotics are usually consumed orally which enables the communication with the intestinal 
enterocytes and gut-associated lymphoid tissues (GALT) in the small intestine. This interaction 
of probiotic strain and hosts cells is important for the controlled production of cytokines and 
chemokines secreted by macrophages and dentritic cells (DCs) (see review Delcenserie et al., 
2008). In the small intestine the low number of resid nt bacteria enables the communication 
between probiotics and intestinal cells more easily than in the colon and therefore probiotics may 
have better competition capability with luminal microbiota of the small intestine than in the colon 
(Walker et al., 2006). The positive effects of probiotics on gastrointestinal disorders may be 
explained most likely by the ability of probiotics to enhance the gut mucosal immune system, 
especially in the small intestine e.g. by increasing mucosal barrier function, preventing apoptosis 
of epithelial cells and decreasing antigen uptake (Walker et al., 2006). Certain probiotic strains 
have been shown in well conducted studies to stimulate and regulate several aspects of innate and 





changes need to be connected to the physiological events before the effects on health and well 
being can be estimated.  
 
Most of the probiotic products available are based on single strain monocultures. The 
combinations of different strains are rare; this may be due to the difficulty to prove the effects of 
the strains with different mechanisms functioning simultaneously or because the interactions 
between the strains may be difficult to predict or even due to the demanding authorization 
procedure. It is noteworthy that combinations may hve a broader possibility in specific disorders 
and in certain conditions if the strains are acting synergistically. Only few groups of researchers 
have been active in studying the possible probiotic effects of multistrain culture combinations 
(Kajander et al, 2008; Myllyluoma et al., 2005; Gionchetti et al., 2007; Drouault-Holowacz et al., 
2008). Those studies have demonstrated the beneficial effects of probiotic combinations in vivo 
for irritable bowel syndrome (IBS) (Kajander et al., 2008; Drouault-Holowacz et al., 2008) 
relieving abdominal pain and distension, for Helicobacter pylori eradication and alleviating of 
symptoms (Myllyluoma et al., 2005), and for preventing the onset of acute pouchitis and 
maintaining remission following antibacterial treatment of acute pouchitis (Gionchetti et al., 
2007). 
1.2.3. Legislative constraints 
 
In Europe, regulation concerning the marketing of functional foods into which probiotic foods are 
included has so far been national and fragmented, and the situation has lead to probiotic product 
launches with diverse and even controversial messag to consumers. In some cases the launches 
were even applying the generic relation to the know probiotic strain of the same species without 
properly conducted intervention trials. These approaches confused consumers and health 
professionals and called for an EU-level consensus on evaluating and regulating the market. 
 
The new legislation on nutrition and health claims entered into force in January 2007 (Regulation 
No. 1924/2006 of the European Parliament and of the Council). The regulation covers to all 
nutrition and health claims made in commercial communication of foods in EU member states. 
The new regulation establishes the claims that can be made, generates lists of generally accepted 
health and nutrition claims and establishes the procedure for the authorization of new claims. 
Claims for probiotic foods can be related to nutritional/functional (article 13) or reduction of a 
risk of a disease action (article 14). A list of accepted nutritional/functional claims e.g. generic 
claims should be published by EFSA in the beginning of the year 2010. In case of the article 14, 
only claims with clear evidence demonstrating the causality between consumption of nutrients 
and indented health benefits will be accepted after judging by EFSA. Besides, all foods having 
nutrition and health claims must meet nutritional requirements based on nutrient intake 
recommendations. At the time being, mainly generic claims are used in the current probiotic 
products in Europe, however, more specific strain-dependent health claims are of great interest 
but they do require more resources and investments from the marketing company because of the 
demanding authorization. 
 
Generally, substantiated scientific documentation fr the health benefits in conjunction to 
technical and administrative information is demanded and in practice the application should 
contain at least the information according to the Joint FAO/WHO Working group (2002) 
guidelines for the evaluation of probiotics in foods. From EFSA point of view safety and strain 






Currently, no positive opinion on applied probiotic dossiers has been given by the agency. Some 
of the main concerns EFSA has expressed on probiotic d ssiers have been that strains have not 
been adequately characterized, and that some of thescience referenced in dossiers referred to 
different strains to those present in the foods for which the claims were being made.  
 
 
Table 3. General selection criteria of probiotic candidates 
 
Strain selection 
o Safety and identification 
o The strain must be safe for consumption, free of pathogenic and toxic 
effects. 
o The strain should be properly identified with the current molecular 
methods (e.g. PFGE DNA/DNA hybridization; 16S RNA sequencing). 
o The strain deposition in an official culture collection is recommended. 
o Biological properties 
o The strain should be able to resist gastrointestinal fluids (acids and bile)  
and should be able to adhere to the human intestinal mucosa. 
o Technological suitability 
o The strain should have good technological properties such as the ability to 
survive during the industrial processing and in the final product in order to 
maintain high viability and activity in the product and at its site of action. 
o The strain should be genetically stable and maintain phenotypic properties. 
Performance and functionality 
o Documented beneficial health effects 
o The strain must have clinically proven health benefits which are proven at 
least in one well defined human study. 
o In case article 14 claims are used, at least two independent DBPC tests 
should be performed. 
o Functional characterization  
 
 
In 2008, the FDA Center for Food Safety and Applied Nutrition published a guidance for 
industry on "Substantiation for Dietary Supplement Claims" (The Federal Food, Drug, and 
Cosmetic Act (21 U.S.C. 343(r)(6), section 403(r)(6)). The guidance covers probiotic foods and 
supplements. Claims allowed for probiotics can be of structure/function, qualified health or 
significant scientific agreement claims. Structure/function statements of food are related to 
normal functioning of the human body and these claims are used most typically on probiotic food 
products as no approval or notification is required for these claims. The pre-approval from FDA 
is needed for the claim for reduction of the risk of disease. 
 
The investigations of the current single strain probiotics have focused primarily on applications 
of Lactobacillus or Bifidobacterium species rather than on dairy Propionibacterium species 
although dairy propionibacteria have a long history f safe use as a dairy starter culture and P. 





the U.S.A. Interestingly, PAB are easily adapting to different environments and they pose several 
interesting features with potent health promoting effects.  
 
1.3. Propionic acid bacteria in food applications and in the gastrointestinal tract 
 
1.3.1. Technological applications of propionic acid bacteria in foods 
 
The genus Propionibacterium belongs to a large heterogeneous group of firmicutes in the class of 
Actinobacteria with high G+C content (>50%) (Stakebrandt et al., 1997). The genus 
Propionibacterium comprises two distinct groups from different habitts, strains found on human 
skin, referred to as the “Cutaneous propionibacteria”, and strains isolated from milk and dairy 
products, referred to as “dairy” or “classical” proi nibacteria. The dairy group of 
propionibacteria includes species P. freudenreichii, P. acidipropionici, P. jensenii, and P. thoenii 
(Cummins and Johnson, 1986). Recently, two new species have been included to the dairy PAB 
group, namely P. cyclohexanicum and P. microaerophilium (Dherbecourt et al., 2006). Especially 
Propionibacterium freudenreichii species have been exploited for decades in big eye (Swiss type) 
cheese production in which their key role is in hole(eye) and flavour formation. In addition, dairy 
type Propionibacterium species are used in vegetable fermentations, in preservation of feeds and 
for the biosynthesis of propionic acid and vitamin B12. P. freudenreichii subspecies 
freudenreichii and shermanii have been granted Qualified Presumption of Safety (QPS) status in 
Europe (Barlow et al., 2007) and the same subspecies are classified as “Generally Recognized As 




Applications of LAB and PAB as bioprotective cultures 
 
The interests in minimal processing systems and in bioprotection of foods and feed have derived 
researchers to seek alternative methods for traditional use of chemicals and high temperature 
treatments for ensuring the high microbial quality of the products. The use of the bioprotective 
capacity of lactic acid bacteria (LAB) and propionibacteria is one of the approaches. The 
antimicrobial action of LAB and PAB is based on various active compounds such as organic 
acids, H2O2, diacetyl, bacteriocins and bacteriocins-like substances acting in most cases 
synergistically. The antimicrobial action of organic acids such as lactate, propionate and acetate 
is based on their ability in undissociated, lipid soluble form to passively diffuse through the cell 
membrane and after entry into the cytoplasm, dissocate into proton and charged derivatives to 
which the cell membrane is impermeable. This intracellular acidification affects the cell 
deleteriously by disrupting the transmembrane delta pH, deactivating the acid-sensitive enzymes, 
and damaging the proteins and DNA. Also charged, anionic moiety of dissociated organic acids 
has detrimental effect on cellular physiology due to a chelating interaction with essential 
elements (Adams, 2001).  
 
Sorbic, benzoic and acetic acids and their salts are used widely in the food industry as 





to prevent moulds and Bacillus occurring in breads (Ponte and Tsen, 1987). Antimicrobial 
proteinaceous compounds derived from LAB and PAB have been investigated and proposed for 
use in food preservation (Holo et al., 2002; Klaenhammer, 1993 ), but so far only nisin, produced 
by certain Lactococcus species, is allowed with restricted use as a food ad itive (EU-guideline, 
No.95/2EG). Nisin is active only against gram-positive bacteria and its antimicrobial spectrum 
does not cover Gram-negative bacteria, yeasts or moulds (Daeschel, 1989). Antifungal 
compounds produced by LAB and PAB would be of great importance for food industry as fungi 
are a frequent cause of spoilage in foods manufactured without chemical additives. Most isolated 
and identified antifungal compounds produced by LAB are low molecular-mass organic 
compounds such as capric acids and short-chain fatty acids (Corsetti et al., 1998), phenyl-lactic 
acids and cyclic dipeptides (Lavermicocca et al.,2003; Ström et al., 2002). Acetate and 
propionate produced by PAB have inhibitory effect towards various fungi (Lind et al, 2005; 
Paster et al., 1999; Razavi-Rohani & Griffiths, 1999) but the production of short chain fatty acids 
(SCFA) and the antifungal activity varies depending o  the growth conditions and on the species 
within propionibacteria (Lind et al., 2005). Additionally, antifungal activity of Propionibacterium 
freudenreichii species have been reported to produce phelyllactic id (PLA) similar to LAB 
(Thierry and Maillard, 2002; Lind et al., 2007). Interestingly, the synergistic properties of 
cocultures of P. jensenii and L. paracasei subsp paracasei has proved to be more effective 
against food spoilage yeasts than the cultures separat ly (Miescher Schwenninger & Meile, 
2004). 
 
Although the activity in studies connected to antimicrobial agents has been intense, only few 
applications have been exploited commercially in food industry, for example MicroGard™ 
fermentates by Danisco A/S. The new era for “green” chemicals may within a few years awaken 




1.3.2. Gut and its microbiota as an ecosystem 
 
The human GI tract can be subdivided into three distinct microbial communities; the upper GI 
tract, the ileum, and the colon. Within these different regions different physicochemical 
environments occur and are reflected in the microbiol g cal populations which are primarily 
modified by different host factors such as age (Abbott, 2004) and host genotype (Bäckhed et al., 
2005). In the upper GI tract rapid transit time, acidic conditions and gastric juices make the 
regions hostile and restrict the microbial populations. Only aciduric gram-positive lactobacilli 
and streptococci can be detected in low levels. Besides the harmless species, the potential 
pathogen, Helicobacter pylori, is able to survive the harsh conditions in about 50% of humans 
(Go, 2002) and under certain circumstances to cause chronic gastritis and eventually even peptic 
ulcer disease (Fox and Wang, 2001). 
 
In the ileum (distal small intestine) the conditions turn less hostile for microbes and the bacterial 
populations comprised of versatile species composition reach cultivable levels between 6 to 8 
log10 CFU g
-1 of luminal content.  The dominant species are gram-negative facultative anaerobic 
bacteria (family Enterobacteriaceae) and obligate anaerobes such as Bacteroides, Veillonella, 






The colon is the main region harboring the majority of the fermentative microbes of the 
gastrointestinal tract, the microbial composition of the colon is complex reaching from levels of 
10 to 12 log10 CFU g
-1 of content consisting of the microbes belonging to main phyla of 
Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria, Fusobacteria and Verrocomicrobia 
(Andersson et al., 2008; Eckburg et al., 2005). This resident microbiota of the intestine has shown 
to be essential for the well-being of the host as the microbiota take part in nutrient processing, 
regulation of host’s fat storage and protection against pathogens (Ley et al., 2006; Xu and 
Gordon, 2003). Besides, the intestinal microbes have a major influence on the physiology of the 
intestinal cells, evidenced by the expression of more than hundred genes of the intestinal cells by 
the resident microbes in the colon via bacteria-bacteria and bacteria-cell dialogue (Hooper & 
Gordon, 2001) and by the maturation of a developing intestinal immune system (Rautava & 
Walker, 2007). On the other hand, the malfunctioning of this GI tract microbiota has been linked 
to certain gastrointestinal diseases (Turroni, 2008). Within the near future the advances in modern 
molecular technology will considerably improve the understanding of the interaction between the 




1.3.3. The role of propionibacteria in the human intestine  
 
The incidence of propionic acid bacteria (PAB) in the human GI tract has not been established as 
well as the incidence of LAB and BIF. Thus, only few studies have been published concerning 
the abundance and occurrence of PAB in the gut. The dairy type of propionic acid bacteria are 
not considered as typical of human microbiota (Rinta-Koski et al., 2001) and the basal counts of 
propionibacteria in human  are reported to be below 5 log10 CFU g
-1  (Bougle et al., 1999; 
Myllyluoma et al., 2007, Jan et al., 2002, Herve et al., 2007) giving an indication that PAB are 
probably minor, transient members of the intestinal microbiota in humans on the contrary to 




In vitro studies have indicated that certain dairy PAB could be able to withstand the conditions of 
the gastrointestinal transit. Interestingly, this has been verified in human intervention studies 
which show that certain strains of dairy PAB (Table 4) have the potential to survive through 
upper GI and to reach the viable cell levels over 6 log10 CFUg
-1, which is generally considered 
sufficient for a probiotic to exert beneficial effects on colon ecology and host physiology (Collins 















Table 4. Dairy propionic acid bacteria strains, doses and cell counts in after administration in 
different matrixes in human intervention studies 
 






, log10 CFU g





SI41 and SI26 
freeze dried in 
powder 









Low, 5.5±1.11  
High, 6.25±0.66  
Jan et al., 
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The microbiota has an essential impact on energy production, renewal and differentiation of GI 
epithelial cells, formation of a barrier against pahogens, synthesis of vitamins and development 
and function of the immune system (Guarner, 2006; Ley, et al., 2006; Turnbaught et al., 2006). 
The intestinal tract is colonized by an extensive and diverse microbial community, which at the 
time is estimated to cover over 1000 species (Egert et al., 2006), however, showing a vast spatial, 
temporal and functional variation (Zoetendal et al., 2004). In a balanced state the complex 
ecosystem of gut does not have adverse acute effects on the wellbeing of the host, but it may be 





stresses. The probiotic approach is developed for balancing of the disturbances. Probiotics may 
not necessarily affect greatly the intestinal microbiota composition or number of cells, but the 
microbiota may respond functionally to probiotics without actual changes in the composition or 
cell numbers (Walker et al., 2006). Still, the precis  impact of the ingestion of probiotic bacteria 
on the functioning of the human gut microbiota is open for discussions (Turroni et al., 2008). 
 
Producers of short chain fatty acids (SCFA) in the gut 
 
The major metabolic function of the anaerobic microbes in the gut is the fermentation of non 
digestible carbohydrates. The metabolism of these complex carbohydrates provides the 
production of the main SCFA (acetate, propionate, and butyrate) and gases hydrogen (H2) and 
carbon dioxide (CO2). Additionally, the protein fermentation leads to formation of SCFA and 
branched chain fatty acids (BCFA). The intestinal epithelium derives 60–70% of its energy needs 
mainly from butyrate, although the other SCFA contribute to some extent (Cumming and 
Macfarlane, 1997).  Butyrate is not only the energy source for the colonic epithelium but it also 
has important effects on the development and gene expression in intestinal cells (Scheppach and 
Weiler, 2004). In addition, it is generally thought to play a protective role against colorectal 
cancer (Archer et al., 1998) and colitis (Christl et al., 1996).  
 
The concentrations of SCFA are dependent on equilibri m between microbial activity and 
colonic absorption. In adults the dominant intestinal microbiota is relatively stable within an 
individual leading to stable microbial activity profiles (Ley et al., 2006). However, the colonic 
absorption may be more variable within an individual, as it is affected by factors such as gut 
transit time, diet, and aging, diseases, drugs and epithelial turnover times (see review, Macfarlane 
& Macfarlane, 2003). Due to the absorption and the eff ct of diet, the accurate quantification of 
SCFA is challenging. However, the production rate of SCFA is estimated to be of the order of 
300-400 mmol/d in human colon (Cummings, 1997). 
 
The major members of colon microbiota able to produce SCFAs are Clostridium, Eubacteria, 
Fusobacterium and Roseburia (Hold et al., 2003; Aminov et al., 2006). Lactobacillus or 
Bifidobacterium species may have an impact on fermentation of complex carbohydrates by 
producing acetic and lactic acids. Interestingly, Bifidobacterium adolescentis has been shown to 
cross-feed the butyrate producing Roseburia sp., Anaerostipes caccae and Eubacteria hallii with 
the lactate and acetate formed in human gut (Belengu r et al., 2006). Theoretically, propionic 
acid bacteria have the potential to impact on intestinal energy balance by utilizing the metabolism 
of carbon substrates via Wood-Werkman pathway (Wood 1981), which leads to production of 
two moles of propionate and one mole of acetate in parallel with CO2 (Figure 1). Prerequisite for 
this metabolic activity is the survival and adhesion of PAB in substantial numbers within the 
colon content, at least transiently. Evidence is already supporting the ability of selected propionic 
acid bacteria to survive and even to maintain the metabolic activity during the GI transit. Humans 
with high population of dairy propionibacteria have been shown to contain enhanced 
concentrations of SCFA (Jan et al., 2002). In addition, certain P. freudenreichii ssp. shermanii 
strains have shown in vivo to transcribe the genes of mRNA encoding the 5S subunit of the 
multimeric transcarboxylase in human microbiota associated rats (Lan et al. 2007) and in healthy 
humans (Herve et al., 2007) indicating the metabolic activity of the strain in the intestinal tract. 
This enzyme, transcarboxylase (methylmalonyl-CoA carboxyltransferace, EC 2.1.3.1.), is an 
essential enzyme in propionic acid fermentation. The subunits 12S, 1.3S and 5S are involved in 





(Deborde, 2002; Hall et al., 2004). The subunit 5S is specific for P. freudenreichii ssp. shermanii 
species (Herve et al., 2007). 
 
    
 
Figure 1. Overall fermentations of glucose to propionic, acetic and succinic acids by Propionibacterium 






One of the mechanisms with which probiotic bacteria m y confer the health of hosts is the 
modulation of intestinal microbiota for example by stimulating bifidobacteria whose presence is 
correlated with a healthy intestinal microbiota, especially in infants (Ouwehand et al., 2002a). In 
adults the population of bifidobacteria varies depending on age and physiological status (Reuter, 
2001; Hopkins et al., 2002) and the actual role of bifidobacteria in adults is still under discussion. 
Nevertheless, certain strains of P. freudenreichii have shown to be able to enhance the growth 
and populations of bifidobacteria in the gut. First ndication was reported by Kaneko et al. (1994) 
of an in vitro bifidogenic effect for cell-free extracts of P. freudenreichii and later the effect was 
reported to be due to the presence of 2- amino-3-carboxy-1,4-naphthoquinone (Mori et al., 1997) 
and 1,4-dihydroxy- 2-naphthoic acid (Isawa et al., 2002). Moreover, independent studies have 
shown that ingestion of P. freudenreichii, under the form of whey cultures, either heat-inactiv ted 
(Satomi et al., 1999) or not (Hojo et al., 2002), or of freeze dried live bacteria (Bougle et al., 
2002), resulted in a higher fecal bifidobacteria concentration in humans. This was linked to an 
increased number of defecations in constipated female volunteers (Hojo et al., 2002). Thus, 









Production of vitamins 
 
Vitamin B12 is essential for the growth and health of humans as it is a crucial cofactor in fatty 
acid, amino acid, carbohydrate and nucleic acid metabolism (Quesada-Chanto et al. 1994). 
Natural synthesis of B12 occurs only in microbes e.g. in the colon. Propionibacteria utilizing the 
Wood-Werkman cycle use the multimeric transcarboxylase (EC 2.1.3.1) which needs cofactors 
B12 (cobalamin), B9 (folic acid), and biotin for the rearrangement of C1 compounds during the 
fermentation. This phenomenon has been known for long and therefore dairy propionibacteria 
have been used for the food-grade industrial production of B12 by fermentation. From 1 kg of 
propionibacteria biomass, approximately 330 g of B12 can be isolated (Deborde, 2002). No 
studies have been carried out of the possible role of PAB as B12 producers in the human 
intervention trial with PAB. 
 
Modulation of enzymatic activities  
 
a) Enhancement of β-galactosidase activity  
 
Lactose intolerance is a common discomfort and a disor er in humans caused by decrease in the 
lactase activity of human enterocytes which in most cases occurs already in childhood (Wang et 
al., 1998). Intolerance, if neglected may lead to malabsorption causing damage for the small 
intestinal mucosa or increase of GI transit time (Schaafsma, 2007). Lactose entering the colon 
may be hydrolyzed by colon microbes having beta-galctosidase activity. One of the benefits 
listed for probiotics is the reduction of lactose intolerance symptoms either by the beta-
galactosidase they produce or by changing the composition of the colon microbiota. Certain 
propionibacteria do have beta-galactosidase activity as shown in study of Zarate et al. (2000) in 
which expression of genes for the beta-galactosidase in P.freudenreichii and P.acidipropionici 
species was reported. 
 
b) Suppression of procarcinogenic enzyme activities  
 
Binding and degradation of pro-carsinogens in the gut is one of the positive outcomes that have 
been connected to probiotics. Intestinal microbes produce several procarcinogenic enzymes, of 
which β-glucuronidase is assumed to contribute to the releas  of carcinogenic moieties from the 
glucurone compounds and β-glucosidase is connected to the formation aglycone compounds in 
the colon (Rowland, 1992; Goldin, 1990). Of the colonic microbes species such as clostridia and 
Bacteroides are known to have high procarcinogenic enzyme activities (Wollowski et al., 2001). 
Contradictionary results with different PAB strain of their effects on intestinal enzyme load have 
been reported. In mice fed with P. freudenreichii CRL 757, or SG1 or P. acidipropionici Q4 or 
CRL1198 strains, P. freudenreichii strains caused no change in β-glucosidase activity of the 
intestinal microbes whereas P. acidipropionici strains significantly reduced β-glucosidase activity 
of mice microbiota (Perez Chaia et al. 1999). In a human study of Hatakka et al. (2008a) P. 
freudenreichii ssp. shermanii JS in combination with L. rhamnosus LC705 was shown to 
decrease the activity of β-glucosidase producing microbes parallel to increasing propionibacteria 
counts. Thus, certain strains of PAB may be useful for preventing elevated levels of β-
glucosidase activities linked loosely to increased risk of colon cancer (Reddy et al., 2000) 







Modulation of the innate immune system 
 
The cross talk between intestinal microbes and intestinal epithelial cells trigger a series of 
immunological mechanisms.  Immunomodulating mechanisms that have been demonstrated with 
certain probiotics include the induction of mucus production, enhanced natural killer cell and 
phagocyte activity, enhanced production of pro- andti-inflammatory cytokines, and induction 
of salivary secretory immunoglobulin A (sIgA) and neutrophils production (see review of Senok 
et al., 2005). In case of candidate probiotic PAB in animal studies, oral administration of 
P.acidipropionici was shown to stimulate phagocytotic activity of the innate immune system in 
mice (Perez Chaia et al., 1995) whereas orally administered P. freudenreichii ssp. shermanii JS 
enhanced proliferation of T- and B-cells in mouse lymphocytes (Kirjavainen et al., 1999). 
Similarly, Adams et al. (2005) reported the enhancement of spleen lymphocytes proliferation by 
P. jensenii 702 strain in an animal study. These observations d  not explain how these organisms 
might induce these effects nor do they explain which bacterial molecules or cellular receptors are 
responsible for them (Delcenserie et. al., 2008). 
 
1.3.5. Safety assessments 
 
Only foods containing novel compounds (Regulation (EC) 258/97) or. Genetically Modified 
Microorganisms (Regulation (EY) 1829/2003) have obtained an official authorization procedure 
requiring the assessment of the safety whereas no auth rization procedure concerning the safety 
assessments of probiotic strains is available. Only the WHO/FAO guidelines (2002) list the 
recommendations for the safety assessments including parameters such as determinations of 
antibiotic resistance patterns, harmful metabolic activities and assessment of side effects during 
human studies. Qualified Presumption of Safety (QPS) approach of EFSA (Barlow et al., 2007) 
sets priorities within the risk assessment of those microorganisms used in food/feed production 
referred to EFSA. The use of any novel strain, unless listed on the QPS (Annex 3), should be 
properly tested for its safety parameters. The methods are left open for the applicant. In the U.S., 
Title 21 of the Code of Federal Regulations (21 CFR) and the FDA Office of Premarket Approval 
lists microorganisms which have a “generally recognized as safe” (GRAS) status.   
 
Propionic acid bacteria belong to a heterogeneous group of Actinobacteria with a high G+C 
content and are included in the Actinomycetale order. Most probiotics currently are of low GC 
content (lactobacilli) or high GC content (bifidobacteria) Gram-positive bacteria (Saxelin et al., 
2005). The first pure culture of Propionibacterium was isolated from Emmental cheese in 1906 
by Orla-Jensen in the year 1909 and still a century later Propionibacterium freudenreichii is the 
main species used at the ripening of Swiss-type cheses, so these species have a long documented 
history of use in foods. According to EFSA scientific committee (Barlow et al., 2007), based on 
their extensive application in the foods and feeds, P. freudenreichii species do not warrant 
specific safety evaluation and therefore P. freudenreichii s granted QPS status. In addition, in the 
USA the species P.freudenreichii is classified as GRAS for use in cheese (Mogensen et al., 
2002).  
 
The use of probiotics in humans has some theoretical adverse risks such as translocation of the 
cells and the potential for antibiotic resistance transfers from probiotic bacteria to potential 
pathogens within the GI tract (Senok et al., 2005). It is accepted that antibiotic non-





infection or unless it can be transferred to potential pathogens (Borriello et al., 2003). The 
vancomycin resistance genes carried by many Lactobacillus species seem to be chromosomally 
located and therefore the genes are not easily transferable to other genera (Tynkkynen et al, 
1999). Dairy PAB are typically resistant to aminoglycosides, the 1st and 2nd generation 
quinolones, colistin, metronidazole and phosphomycin (Madec et al.,1994; Chamba et al., 2007). 
Antibiotic resistance in dairy propionibacteria does not appear to be plasmid-encoded (Rehberger 
and Glatz, 1990) although the issue is not studied widely. 
 
1.4. Approaches to overcome the technological and physiological challenges 
 
In order to provide the desired health benefits, a probiotic strain must have good technological 
properties (industrial scale cultivation with high survival rates during processing and storage) and 
should be incorporated into food products without losing viability and functionality and without 
creating unpleasant flavors or texture (Mattila-Sandholm et al., 2002; Ross et al., 2005). Ability 
to adapt to different stresses during the culture production and during the transit in the intestine is 
considered as an essential characteristic for a probiotic strain facing several challenges during the 
steps from manufacturing until the final destination at the host intestine (Lacroix & Yildrim, 
2007). Tolerance to harsh conditions can be due to an intrinsic resistance or to an adaptive 
response (Segal and Ron, 1998) and many of the currnt p obiotic strains have been chosen by 
their tolerance to the digestive stresses which have been studied by screening for an intrinsic 
resistance of acid and bile salts in vitro. If the strain does not have either intrinsic or adaptive 
response against the stresses, the cells can be prot cted with external layers as in 




Microbes have evolved stress-sensing systems reacting on signals from the environment in order 
to keep the homeostasis within the cell in balance. Th  homeostasis in unfavorable environment 
is maintained with physiological changes controlled by gene expression (Segal and Ron, 1998). 
Genes implicated in stress response are numerous and for example in LAB the levels of 
characterization of their actual role and regulation differ widely between species. General stress 
responses rely on the coordinated expression of genes a d the synthesis of stress-response 
proteins which alter different cellular processes such as cell division, DNA metabolism, 
membrane composition and transport (van de Guchte et al., 2002). In LAB, stress proteins 
synthesis has been studied in response to acidification, osmotic stress and high temperatures 
mainly with starter cultures. The current information is thoroughly reviewed by van de Guchte et 
al. (2002) and Lacroix & Yildirim (2007).  
 
Propionibacteria applied technologically faces primarily the stresses caused by low pH and high 
temperature during the food processing and when applied as probiotic the stresses caused by 
gastrointestinal fluids during the passage through GI tract. PAB seem to have a good intrinsic 
ability to adapt and survive in harsh environments (Leverrier et al., 2004) and some 
P.freudenreichii strains withstand well the high temperatures and high saline concentrations e.g. 
during the Emmental cheese manufacture (Langsrud and Reinbold, 1973). However, a great 





leads to drastic morphological changes (Jan et al., 2001) and at pH 2 to cell death caused by 
intracellular material leakage from non-adapted cells whereas the bile challenge is less 
deleterious (Leverrier et al., 2003). The acid tolerance response (ATR) can be triggered by a 
transient exposure to pH 5 which affords protection t ward acid challenge at pH 2 both the 
physiological and morphological levels (Jan et al, 2001). The physiological state of the cells 
during lethal treatment plays an important role in the response to bile salts, as stationary-phase 
bacteria appear less sensitive than exponentially growing cells (Jan et al., 2000; Leverrier et al, 
2003). Cross-protection between bile salts and heatad ptation increased the stress tolerance, 
whereas heat and acid responses did not present significant cross-protection in P. freudenreichii 
(Leverrier et al., 2004). In conclusion, the stress su ceptibility of propionic acid bacteria seems to 
be species and even strain dependent (Jan et al., 2002; Anastasiou et al., 2006) and by proper 
strain selection or by stress adaptation, stress tolerant strain can be chosen.  
 
External techniques for protecting probiotic cells 
 
The viability of probiotic strain can be enhanced by cell protection with new technologies such as 
microencapsulation. In microencapsulation the inner matrix i.e. probiotic cells are sealed with a 
continuous coating inside of a microcapsule core which protects the cells from extremes of heat, 
moisture (Doleyres and Lacroix, 2005) and gastrointestinal fluids (Kailasapathy, 2002) and 
which provides controlled release of the probiotics at the target site (Chen et al., 2005). The 
semipermeable, thin and strong wall of the microcapsule allows nutrients and metabolites to 
diffuse through the material easily and at the same ti  keep the cells within the capsule (Chen et 
al., 2005). With respect to probiotics, the most often reported benefit of microencapsulation is 
enhanced viability in the different food matrixes. Microencapsulation techniques have not been 






2. AIMS OF THE STUDY 
 
The purpose of the study was to assess the probiotic and the technological potential of 
Propionibacterium freudenreichii ssp. shermanii JS and Lactobacillus rhamnosus LC705 applied 
in a culture combination in different food matrixes. Additionally, the in vitro studies of 
Propionibacterium freudenreichii ssp. shermanii JS assessed the strain’s probiotic parameters 
such as the viability during the acid and bile treatments and the safety aspects such as antibiotic 
susceptibility. 
 
The specific aims of the studies were, 
• To characterize the combined antimicrobial activity of the strains LC705 and JS by 
assessing the bioprotective effectiveness against common food spoilage yeasts/moulds 
and spore forming bacteria in food applications (Study I) 
• To assess in vitro adhesion (Study II), upper GI tract tolerance (Study V) and antibiotic 
susceptibility (Study V) of the strain JS  
• To assess the in vivo gastrointestinal survival of the strains JS and LC705 administered in 
whey-based orange juice by healthy adult volunteers (Study IV and V) and to assess the 
potential of the strains LC705 and JS to relief constipation in the elderly (III) and in the 
healthy adults (IV) 
• To confirm the conventional biochemical identificaton of the JS strain in faecal samples 
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3. MATERIALS AND METHODS 
 
The detailed descriptions of the methods used in the s udies are presented in the original articles 
and therefore the methods are not repeated in detail in h s section. 
 
3.1. Microbes  
 
The probiotic candidates  
 
The studies focused on two probiotic candidates (Table 5) which were assessed for their 
combined effects as a protective culture in fermented dairy foods and in wheat bread (Study 1), 
for their gastric survival in healthy adults (Study IV and V) and for their possible beneficial role 
on the treatment of constipation at the institutionalized elderly (Study III) and healthy adults 
(Study IV). Safety related parameters of strain JS were assessed in the Study II, III, and V.   
 
The basic properties of Lactobacillus rhamnosus LC705 have been published by Tuomola et al. 
(2000) and Mäyrä-Mäkinen et al. (2002).  
 
Table 5. The candidate probiotic strains 
 
Strain Culture collection Growth condition Study 
Lactobacillus 
rhamnosus LC705 
DSM 7061, Valio 
Ltd., Finland 
MRS, LAMVAB 
3 d / 37 C 




DSM 7076, Valio 
Ltd., Finland 
PPA, YEL and 
MRS/ 48 h and 7 d 
/30C 




L. rhamnosus GG (ATCC 53103, Valio Ltd., Finland), Bifidobacterium lactis Bb12 (Hansen A/S, 
Denmark) and B. longum (nee infantis ) BB99 (Valio Ltd., Finland) were used in the study II. 
L.reuterii ING 1 (Ingman, Finland) was used in the study III and L. rhamnosus E-97800 (VTT, 
Finland) was used in the study IV. 
 
P. freudenreichii ssp. freudenreichii P131 (Valio Ltd., Finland), P. freudenreichii ssp. 
freudenreichii ITG P20 (Institut Technique Francais des Fromages; ITFF, France) and P. 
freudenreichii ssp. freudenreichii ITG P23 (ITFF, France),  P. freudenreichii ssp. freudenreichii 
NCIMB 5959T (National Collection  of Industrial, Food and Marine Bacteria; NCIMB Ltd., UK) 







3.2. Antimicrobial activity of the P. freudenreichii ssp. shermanii JS and L. rhamnosus 
LC705 culture (Study I) 
 
The antimicrobial activities of the JS and LC705 as single strains and the culture combination 
were detected on conventional tests in vitro, previously (FI92498). The aim in antimicrobial 
study (study I) was to evaluate the bioprotective activity of the combination in real food systems. 
Commercial production processes of the products (yogurt, quark and wheat bread) were 
simulated and the products were artificially inoculated with contaminants isolated from the 
similar products (Table 6). The microbiological and chemical quality of the products was 
followed weekly during the storage time. 
 
Table 6. Contaminants, growth parameters and their origin (Study I) 
 
Product Contaminant Origin Growth parameters  
Yogurt and Quark Rhodotorula rubra 
RHO 
Fermented milk YM 25C / 2 d 
Yogurt and quark Pichia quilermondii 
PQ 
Fermented milk YM 25C / 2 d 
Wheat bread Bacillus subtilis 
P.2.94 
Ropy wheat bread BHI 37C / 24 h 
Wheat bread Bacillus 
licheniformis P.1.94 




Table 7. The growth media for the enumeration of microbes with plate counts (Study I) 
 
Assay Medium Conditions 
Total LAB MRS-agara 3 d 37C 
L. rhamnosus LC705 MRSV-agar with 0.005% (w/v) vancomycin 3 d 37C 
Propionic acid bacteria Mod. Sodium-lactate agar (YEL) with 1% (w/v) 
β-glyserolphosphate (PPA) 
7 d 30C 
Yeasts and molds YCG-agar a  3 d 25C 
Bacillus spp. Phenol Red Egg Yolk Polymyxin agar a 20-24 h 37C 








Preparation of contaminants (Study I) 
 
Bacillus spore suspension in a wheat bread trial 
 
Bacillus subtilis and B. licheniformis were isolated and identified from the ropy bread in the 
beginning of the study. The spore suspension of Bacillus subtilis and B. licheniformis strains was 
produced by harvesting the spores and vegetative cells grown on Nutrient agar enriched with 
0.003% (w/v) MnSO4x4H2O for 48 h at 37º C aerobically by centrifugation (4500 g for 10 min at 
4ºC) and washing with sterile water (after which a stock solution was prepared in a sterile water.) 
In order to destroy the vegetative cells, the stock solution was heated for 10 min at 80ºC. The 
spore concentration in stock solution was 9.9 log10 CFU ml
-1. The inoculum level was 2.5 log10 
CFU g-1 dough.  
 
Yeasts suspensions in fermented milk products trial 
 
Rhodotorula rubra and Pichia quilermondii were isolated from relevant contaminated fermented 
milk products in the beginning of the study. Yeasts were grown in YM-broth at optimal 
conditions for 2 d after which vegetative cells were inoculated in to products at a level of 2.5 
CFU log10 g
-1 quarks and 2.5 CFU log10 g






Table 8. Preparation of products (Study I, III, IV and V) 
  




Quark L. rhamnosus LC705 
and P. freudenreichii 
ssp.shermanii JS 
1) 7 log10 CFU g
-1 quark 
2) 6 log10 CFU g
-1 quark 
Probat 505*  I (technological use) 
Yogurt L. rhamnosus LC705 
and P. freudenreichii 
ssp.shermanii JS 
7 log10  CFU g
-1 yoghurt V2 * I (technological use) 
Wheat bread L. rhamnosus LC705 
and P. freudenreichii 
ssp.shermanii JS 
8 log10 CFU g
-1 
sourdough 
None I (technological use) 
3 Fruit juice® L. rhamnosus LC705 
and P. freudenreichii 
ssp.shermanii PS 
8 log10  CFU ml





L. rhamnosus LC705 
and P. freudenreichii 
ssp.shermanii PS 
8 log10 CFU ml
-1 juice None IV, V (probiotic use) 
 







3.3. In vitro characterization of P. freudenreichii ssp. shermanii JS (Studies II and V) 
 
3.3.1. In vitro gastric tolerance of P. freudenreichii ssp. shermanii JS  
 
The in vitro gastric tolerance of P. freudenreichii ssp. shermanii JS was evaluated at low pH 
with HCl acid and at high bile concentration as follows, the propionibacteria strains were 
cultivated anaerobically in propioni medium (PA-broth, pH 7.3) for 3 d at 30°C (stationary 
growth phase). The survival of the propionibacteria str ins during bile exposure was studied 
in PA-broth supplemented with 0.3 % or 0.5 % (w/v) oxgall powder (Bile bovine, Sigma B-
3883, Sigma-Aldrich, St. Lois, MO, USA) by inoculating the broth with 1% of stationary 
growth phase culture and by enumerating the viable cell counts after 0 and 3 h of incubation 
at 30°C. The acid tolerance test was performed in whey permeate medium (WPM-broth) 
adjusted with 37% HCl to pH of 6.5, 4.0, 3.0 and 2.0. WPM-broth was inoculated with 1% of 
stationary growth phase culture and incubated for 1, 2 and 3 hours at 30°C, after which viable 
cell counts were enumerated. Viable cell counts from both experiments were determined on 
PPA-agar by incubating the plates anaerobically for 7 d at 30°C 
 
3.3.2. Safety related in vitro studies  
 
Safety related parameters such as adhesion and antibiotic susceptibilities of P. freudenreichii 
ssp. shermanii JS were evaluated with in vitro tests.  
 
Adhesion studies (II) 
 
In vitro adhesion of P. freudenreichii ssp. shermanii JS was performed in mucus isolated 
from healthy part of resected human colonic tissue (Ouwehand et al., 2002b) and the non-
specific adhesion was performed by using immobilized Bovine Serum albumin (BSA). Both 
the mucus and BSA were passively immobilized on polystyrene microtitre plates. The use of 
resected human intestinal material was approved by the joint ethical committee of the 
University of Turku and Turku University Central Hospital. The adhesion assay was 
performed according to the procedure described in details by Ouwehand et al. (2001). The 
bacteria were radiolabelled with methyl-1,2,-3H thymidine and after the growth for late 
exponential phase at optimum growth conditions the cell concentrations were adjusted for the 
optimal densities of 7-8 log10 CFU ml
-1 and added at a volume of 100 µl into mucus or BSA 
coated microtitre plate wells. Radioactivity was determined by liquid scintillation and the 
adhesion was expressed as the percentage of radioactivity recovered after adhesion, relative 
to the radioactivity in the bacterial suspensions added to the immobilized mucus.  
 
Minimal inhibitory concentration (MIC) of antibiotics (Study V) 
 
Determination of the minimal inhibitory concentration (MIC) of antibiotics was performed on 
VetMICTM E-cocci microdilution panel (National Veterinary Institute, Uppsala, Sweden) by 
using the Lactic acid bacteria Susceptibility test Medium (LSM; Klare et al. 2005) consisting 





medium (LabM, Bury, UK). The assay included the following antibiotics, ampicillin, 
erythromycin, virginiamycin, gentamicin, streptomycin, kanamycin, tetracycline, 
chloramphenicol, vancomycin, narasin, bacitracin and li ezolid in a concentration range of 
0.125 – 1024 µg mL-1. Briefly, P. freudenreichii ssp. shermanii JS, P131, NCIMB 5959T and 
NCIMB 10583 were cultivated in LSM broth for 48 h at 30°C anaerobically. For the final 
inoculum, 1 mL of propionibacteria culture grown for 3 d at 30°C was suspended aseptically 
to sterile saline until a density corresponding to a spectrophotometric OD625 of 0.16-0.2 was 
reached. This saline suspension was then diluted 1:1000 in LSM broth to obtain a final 
concentration of 5.5-5.8 log10 cfu mL
-1. For each well in VetMICTM E-cocci microdilution 
plate, a 100 µL of this inoculum was added within 30 min after the preparation of the final 
inoculum. The wells were sealed with a transparent covering tape and the panel was 
incubated for 3 days at 30°C, anaerobically. The growth of the culture in the w lls was 
assessed visually. The MIC was defined as the lowest concentration of antibiotic giving a 
complete inhibition of visible growth out of three r peated experiments. 
 
Characterization of Enzyme Activity Profiles (Study V) 
 
In vitro enzyme activity profiles were detected by the chromogenic, semiquantitative API 
ZYM system (bioMérieux sa, Marcy-l’Etoile, France) according to the manufacturer’s 
instructions. Briefly, strains were harvested, washed and suspended into API ZYM medium 
and adjusted to cell count of 8 log10 CFU mL
-1. A 65 µl of this suspension was added to each 
well and then incubated for 4 h at 30°C.  The reaction was stopped by adding the reagent 
Zym A and the colour development was obtained by adding the reagent Zym B. Enzyme 
activity was detected through colour reaction by comparing the colour intensity to the colour 
reading chart provided by the manufacturer and expressed as nM of substrate hydrolysed / 65 
µL of culture on a scale of 0 (no activity) to ≥40nM (high activity). The cell numbers in the 
wells were enumerated by plate counting on PPA-agar for 7 days at 30°C and they were 
8.0±0.1 log10 cfu mL
-1 for the JS strain and 7.9±0 log10 cfu mL
-1 for the P131 and NCIMB 
5959T strains. The test was performed twice for all strains. 
 
 
3.4. Pilot assessment of the combination of P. freudenreichii ssp. shermanii JS and L. 
rhamnosus LC705 in human intervention studies (Studies III – IV) 
 
The aim in the intervention studies was to assess in vivo gastrointestinal survival of the two 
candidate probiotics of L. rhamnosus LC705 (study IV) and P. freudenreichii ssp. shermanii 
JS (study V). The enumerations were performed by conventional plate counting (Table 10) 
from frozen fecal samples and isolates resembling the ingested probiotic strains were 
identified with current molecular methods (Table 11).  The effects of the probiotic strains on 
intestinal well being of elderly (study III), and of healthy adults (Study IV) were followed by 
recording the gastrointestinal symptoms. The effects of the strains on humoral immune 
responses on the healthy adults were performed by enum rating the indicators of the innate 
immune system (immunoglobulin secreting cells (ISCs), expression of Fcα-receptors and 






Elderly volunteers (n=28) were enrolled in the Study III, and healthy adult volunteers (n=22) 
were recruited for the studies IV and V. The studies w re approved by the Ethical Committee 
of the Hospital District of Varsinais-Suomi. A signed informed consent was obtained from 
every volunteer. 
 
Table 9. Study designs in human intervention trials (Studies III, IV and V)  
 
Run-in  Intervention Washout End point Study 
3 wks  
Fruit juice 
3 wks 






















• L. rhamnosus 
Lc705 cell 
numbers 












• P. freudenreichii 








Table 10. Cell count enumerations of L. rhamnosus and P. freudenreichii ssp. shermanii 
(Studies IV and V) 
 
Analysis Method Conditions Reference 
L. rhamnosus  LAMVAB 3 d; 37C; 
microaerophilically 
 






7 d; 30C; 
anaerobically 
 
mod. Malik et al.  
 
Colonies resembling L. rhamnosus LC705 on LAMVAB agar plates (study IV) were selected 
for genotyping with randomly amplified polymorphic DNA (RAPD) using primers listed in 
Table (11) and as described by Alander et al. (2001).  
 
Presumptive propionibacteria colonies with light yellow colors were isolated and purified on 
PPA-agar (study V). Preliminary identification of the pure cultures of P. freudenreichii ssp. 
shermanii isolates was based on gram-staining, catalase activity, fermentation of lactose and 
sucrose, nitrate reduction (Nitrate test, Merck) and carbohydrate fermentation by API 50 CH 
(bioMérieux sa). The typing of the strains was performed with RAPD according to Fessler et 
al. (1998) with primers in combination listed in Table (11) and with pulsed field 
electrophoresis (PFGE) analysis with restriction enzymes XbaI and SspI (New England 






Table 11. Oligonucleotides used for the randomly amplified polymorphic DNA identification 
in the Study IV and V. 
 








Alander et al., 2001 
RAPD-primer CGAGCCGTC Propionibacterium 
 RAPD-primer ACGCGCCCT 
Fessler et al.,1998 
 
 
Table 12. Parameters of gut wellbeing  
 




Questionnaire  III and IV 
Fecal mucin Colorimetric assay with Alcian 
blue 
Hall et al.,1980 III 
ISCs Enumeration of 
immunoglobulin secreting 
cells (ISCs) 
Kaila et al.,1992 IV 
CD89, CD35 and 
CD116 
Expression of Fcα -, and 
complement 1 and 3 receptors 





3.5. Statistical analysis 
 
Bacterial cell numbers were transformed into log10 values before any treatment. In the 
adhesion study (Study II) the results from the adhesion experiments were expressed as the 
average (± standard deviation) of at least three independent experiments. Each adhesion 
experiment was performed with four parallels. The stati tical significance in adhesion 
between the strains, to the substrata and with the incubation time was tested by using the t-
test (paired, two tailed). In the studies III and IV, The Mann-Whitney U-test was used for the 
comparison between the groups and Wilcoxon’s signed-rank test was used for the comparison 
within the group.  Bacterial cell numbers in the human studies were presented separately for 
each subject. The statistical significance of differences in the cell counts of the strain LC705 
(Study IV) and JS (study (V) at baseline versus after consumption and after follow-up within 







4. SUMMARY OF RESULTS  
 
4.1. Technological applicability as a bioprotective culture 
 
In this study, the antimicrobial potential of the combination P. freudenreichii ssp. shermanii 
JS and L. rhamnosus LC705 was studied in laboratory scale in quark against yeast R. rubra 
RHO, in yogurt against yeast P. quilermondii PQ, and in wheat bread against Bacillus spp.  
Fresh quark mass was obtained from the commercial production process whereas the yogurt 
and wheat bread were prepared in the laboratory according to commercial manufacturing 
procedures. The products were contaminated with microbes isolated from similar products by 
adding contaminants at relevant levels to the products before packing. 
 
The initial level of 0.1 % (v/v) of the protective culture equivalent to 7.3 log10 CFU g
-1 
product of both strain inhibited the growth of R. rubra RHO in quark whereas a one log lower 
concentration of the strains had no inhibitory effect on the growth of the contaminant RHO. 
The yeast RHO reached the cell count of over 6 log10 CFU g
-1 product in three weeks of 
storage at 6°C rendering both the control and the test product with 0.01% of protective 
culture unacceptable. The production of acetic acid n  diacetyl was higher in quark with 
protective culture of 0.1 % (v/v) than in control (Table 13). In yoghurt, both of the 
contaminants (RHO and PQ) were inhibited by the protective culture with a level of 7.3 log10 
CFU g-1. In control yoghurt, R. rubra RHO and P. quilermondii PQ reached cell counts of 3 
log10 CFU g
-1 and over 7 log10 CFU g
-1 , respectively, after four weeks of storage at 6°C.   
 
Table 13. Levels of organic acids, diacetyl, ethanol and yeasts in quark and yogurt 
manufactured with basic starter and with the addition of 0.1% protective culture of 
L.rhamnosus LC705 and P. freudenreichii ssp. shermanii JS after storage for 3 weeks at 6° C 
 
 Quark Yoghurt 
 Control Protective culture  
(log 7 CFU g-1) 
Control Protective culture 
(log 7 CFU g-1) 
Lactic acid, % 0.72 0.73 0.94 0.94 
Propionic acid, 
mg.100 g-1 
<0.5 <0.5 <0.5 2.0 
Acetic acid, mg.100 
g-1 
38.0 64.0 5.0 10.0 
Diacetyl,  
mg. kg-1 
0.6 49.0 <0.5 24.0 
Ethanol,  
mg. kg-1 
10.0 15.0 220.0 7.0 
Bentzoic acid, 
mg. kg-1 
Nt Nt <10 <10 
Yeast count, log 
CFU g-1 product 















The optimal process applying the combination of L. rhamnosus LC705 and P. freudenreichii 
ssp.shermanii JS for the use of sour dough in wheat bread was developed. The initial level of 
8 log10 CFU g
-1 and 8.5 log10 CFU g
-1 sourdough fermented for 10 h with LC705 and JS, 
respectively, inhibited the growth of Bacillus species in wheat bread totally at the addition 
level of 10% of sourdough (v/v) to the final dough at RH<20% and at the level of 15% of 
sourdough (v/v) at RH 70% conditions. In the control breads Bacillus sp. reached the cell 
counts of over 4 log10 CFUg
-1 already in two days at RH 70%. No antimicrobial effect against 
Bacillus sp. was noticed in bread manufactured with 10% of sourdough fermented for 4 h. 
Changes in the lactic acid concentration and pH was observed in breads (Table 14). 
 
Table 14.  The effect of duration of sour dough ferm ntation on pH, total titratable acidity 
(TTA) and concentration of organic acids in wheat bread. Breads were made with sour dough 
fermented with an initial level of both L. rhamnosus LC705 and P. freudenreichii ssp. 
shermanii JS 1-3x108 cells g-1 dough for 4, 10 or 20 h by adding 20% of the sour dough for 
the final dough. Control breads were fermented withou  the bioprotective culture for 4, 10 or 
20 h by adding 10% sour dough to the dough. 
  
 Fermentation time 
 4 h 10 h 20 h 
 Control PC Control PC Control PC 
Lactic acid, % <0.04 0.04 <0.04 0.17 <0.04 0.23 
Propionic acid, 
mg.100 g-1 
1.0 4.0 1.0 5.0 1.0 5.0 
Acetic acid, 
mg.100 g-1 
19.0 19.0 18.0 19.0 19.0 19.0 
pH 5.5 5.5 5.5 4.8 5.5 4.6 
TTA, mL 3.0 3.2 3.0 4.5 2.8 4.7 
 
 
4.2. The in vitro characterization of P. freudenreichii ssp. shermanii JS as a candidate 
probiotic strain 
 
According to the current probiotic concept, each candidate probiotic strain has to be 
characterized individually, therefore P. freudenreichii ssp. shermanii JS was studied for its 
acid and bile tolerance (study V) and for its adhesion to intestinal mucosa (Study II). In order 
to eliminate the possibility of harmful traits of P. freudenreichii ssp. shermanii JS, in vitro 
assessment of safety related aspects were monitored by analyzing antibiotic susceptibility as 
minimal inhibitory concentration of antibiotics (MIC) on VetMIC™ E-cocci microdilution 
panel, and by monitoring enzyme activity profile onsemiquantitative API ZYM system 






The strain P. freudenreichii ssp. shermanii JS survived well in the in vitro tests evaluating its 
ability to survive during the transit of the upper part of the gastrointestinal tract. The 
treatment for 3 hours at pH value over pH 2 did not have any lethal effects on cells, but at pH 
2 the cells were suffering of the acidity and the count dropped drastically under the detection 
level (3 log10 CFU ml
-1)(Table 15). Bile at a concentration of 0.5% was well tolerated by the 
strain JS.  
 
 
Table 15. The effect of a low pH (pH 2, pH 3 and pH 4) and a high bile salt concentration 
(0.5%) on viability of P. freudenreichii ssp. shermanii JS during 3 hours treatment.     
 
Cell numbers log10 cfu ml
-1 (std) during 3 hours 





 0 hour 1 hour 2 hours 3 hours 
pH 4 7.8 (0.02) 7.9 (0.02) 7.8 (0.07) 




7.8 (0.06) 6.7 (0.30) 3.6 (0.55) <3.0 (0.0) 
JS 
Bile 0.5% 7.8 (0.09) n.t. n.t. 7.8 (0.05) 
 
Data given as mean values and standard deviations expressed as log10cfu/ml (std.), n=3  
Detection limit 3 log 10 g 
–1, n.t.  not determined.    
 
 
Adhesion (Study II) 
 
Adhesion was studied with mucus adhesion model with colonic mucosa as described by 
Ouwehand et al. (2001). P. freudenreichii ssp. shermanii JS was observed to adhere only 
moderately to all tested substrata without significant difference in adhesion to intestinal 
mucus (0.4±0.2%) or BSA (0.2 ±0.1%). The influence of other bacteria adhering prior to the 
mucus did not have any effect on the adhesion of JS nor did the incubation time (Data in the 
Study II).  
 
 
Enzyme activity profiles 
 
P. freudenreichii ssp. shermanii JS showed a high β-galactosidase activity determined in 
vitro with the semiquantitative API ZYM system. No β-glucosidase activity was noticed (data 
in Study II). 
 
 
Antibiotic MIC (Study V) 
  
The antibiotic susceptibility of the P. freudenreichii strains JS did not differ from other 
propionibacteria strains measured on the VetMICTM broth microdilution assay (Table 16). 
The strain JS showed low minimal inhibitory concentration (MIC <4 µg/ml) for ampicillin, 
erythromycin, virginiamycin, tetracycline, chloramphenicol, vancomycin, narasin, bacitracin, 








Table 16. Antibiotic susceptibilities of P. freudenreichii ssp.shermanii JS, P. freudenreichii 
ssp. freudenreichii 131, P. freudenreichii ssp. freudenreichii NCIMB5959T and P. 
freudenreichii ssp. shermanii NCIMB10585 on VetMICTM broth microdilution assay. 
 




Ampicillin, µg/ml 0.25 2.0 <0.125 0.25 
Erythromycin, µg/ml <0.25 <0.25 <0.25 <0.25 
Virginiamycin, µg/ml <0.25 1.0 0.50 0.50 
Gentamicin, µg/ml 8 4 8 16 
Streptomycin, µg/ml 8 16 16 32 
Kanamycin, µg/ml 32 64 64 128 
Tetracycline, µg/ml 1.0 1.0 <0.25 0.50 
Chloramphenicol, µg/ml 2.0 1.0 0.50 1.0 
Vancomycin, µg/ml 1.0 1.0 1.0 1.0 
Narasin, µg/ml 0.125 0.50 1.0 0.50 
Bacitracin, U/ml <1 < 1 < 1 < 1 
Linezolid, µg/ml 0.50 2.0 1.0 0.50 
 
4.3. Pilot assessment of the combination of P. freudenreichii ssp. shermanii JS and L. 
rhamnosus LC705 in human intervention studies (Studies III – IV) 
4.3.1. Safety related aspects of P. freudenreichii ssp. shermanii JS and L. rhamnosus 
LC705 administered by elderly subjects (Study III) 
 
Parameters such as fecal azoreductase activity, pH and mucin content indicating changes in 
the intestinal microbiota were assessed in elderly subjects who were administering the 
combination of the strains P. freudenreichii ssp. shermanii JS and L. rhamnosus LC705 in 
fruit juice (Hedelmätarha®) with a daily dose of 10log10 CFU for two weeks. A trend of a 
slight reduction in the fecal azoreductase activity in the elderly (Table 17) was noticed in vivo 
with the combination of JS and LC705 strains. The reduction was statistically significant 
(p<0.05) from the baseline to consumption. No statitically significant changes were 
observed in pH or in faecal mucin excretion (data in Study III).  
 
 
Table 17. The effect of the consumption of L. rhamnosus LC705 and P. freudenreichii ssp. 






Group Baseline Treatment Follow-up 
Control 29.5 ±0.9 29.2 ±2.3 29.4 ±1.8 
JS+LC705 30.3 ±2.4 28.1 ±3.0 28.2 ±2.5 
 
 
4.3.2. Immunomodulatory parameters measured from healthy adults (Study IV) 
 
Parameters such as the number of immunoglobulin secreting cells (ISCs) and the expression 
of Fcα-receptor for IgA and complement receptors 1 and 3 for neutrophils and monocytes 
were assessed from peripheral blood samples in healthy dults administering whey-based 
orange juice (Hedelmätarha®, Valio Ltd., Finland) daily for two weeks. During the 
administration of fruit juice supplemented with L .rhamnosus LC705 and P. freudenreichii 
ssp. shermanii JS a decreasing frequency of IgA-secreting cells wa observed from baseline 
to consumption period, mean number decreased from 1427 to 943 and the median change-% 
was 21.4% (p=0.02). A slight but not significant decrease was seen in the expression of Fcα-
receptor on neutrophils during the same period, the mean number decreased from 8.63 to 7.79 
and the median change was 7.45% (Table 18). No significa t changes in IgG or IgM-
secreting cells or in Fcα-receptor on monocytes were detected (data in publication IV).  
 
Table 18. Number and median change-% of ISC/106 mononuclear IgA cells and of FcαR in 
neutrophils at baseline, consumption and follow up periods in subjects receiving juice 
supplemented with L. rhamnosus LC705 and P. freudenreichii ssp. shermanii JS.  
   














changes (%) in 
FcαR 
Baseline 1427 (913-2955) 8.63 (7.74-9.39)   
Consumption 943 (560-1828) 7.79 (7.21-8.53) -21.4*  
(-40 to -14) 
-7.45  
(+24.4 to -3.87) 
Follow-up 1322 (1188-
1758) 
5.77 (5.05-10.10) +27.5  
(-11 to +99) 
+10.49  
(-34.7 to +23.1) 
* Asteric denote for statistical significance (* p<0.05) tested by Wilcoxon test. 
 
 
4.3.3. Survival of JS and LC705 in vivo 
  
In vivo gastric survival of P. freudenreichii ssp. shermanii JS and L. rhamnosus LC705 was 
measured in single-blind randomized parallel intervention studies with 2-week periods 
(baseline, consumption, follow-up). The healthy adults were consuming the strains in whey-
based orange juice (pH 3.8±0.2) Hedelmätarha® (Valio Ltd) with a daily dose of 10 log10 
CFU during the study period. The fecal samples were collected after each period and 
analyzed by conventional cultivation methods. Isolates resembling the ingested strains were 
selected for further biochemical identifications and finally for genotyping in order to confirm 






L. rhamnosus LC705 and P. freudenreichii ssp. shermanii JS survived at high numbers and 
were recovered at a concentration exceeding over 6 log10 CFU g
-1  during the consumption 
period (Fig. 1a and 1b), JS reaching even the higher mean viable cell numbers (7.6 log10 CFU 
g-1 )  than LC705 (6.4 log10 CFU g
-1 ). No isolates representing JS-type were found from the 
baseline samples whereas in five subjects isolates representing the identical RAPD type with 











































































Figure 2a and 2b. Cell numbers and the detection frequency of L. rhamnosus LC705 (fig.2a) and P. 
freudenreichii ssp. shermanii JS (fig.2b) in faecal samples obtained at the end of baseline, 
consumption of fruit juice containing the strains LC705 and JS and follow-up periods (2 weeks each). 
The bold line shows the mean count of the strains in the faecal samples of 10 subjects and the thinner 







4.3.4. Identification of the JS strain (Study V) and LC705 (Study IV) 
 
The biochemical identification of P. freudenreichii ssp. shermanii JS isolates from the fecal 
samples was confirmed by 23S rDNA restriction analysis and by RAPD. The amplified 23S 
rDNA of strain JS gave a corresponding restriction pattern to the P. freudenreichii-type strain 
NCIMB 5959T, while the type strains P. jensenii ATCC 4868, P. thoenii ATCC 4874 and P. 
acidipropionici ATCC 4875 gave distinct restriction profiles. Isolates of strain JS did not 
reduce nitrate, which classified the strain to subspecies shermanii. Strain JS was 
differentiated from other strains representing the same subspecies by RAPD, which gave a 





Figure.3. RAPD profile of Propionibacterium strains. Lanes 1-10, P. jensenii ATCC 4868T (1), P. 
thoenii ATCC 4874T, P. acidipropionici DSM 20272 (3), P. freudenreichii ssp.freudenreichii strain 
NCIMB 5959T (4), 131 (5), ITG P20 (6), ITG P23 (7), P. freudenreichii ssp. shermanii strains 
NCIMB 10585 (8) and JS (9). Molecular weight marker λ PstI (lane 10). 
 
 
The identification of L. rhamnosus LC705 isolated from the fecal samples was confirmed by 
RAPD with OPA-3 primers. Additional primers were used in the RAPD analysis in order to 
increase the discriminatory power of the method. In total 135 isolates were compared by 
RAPD to the pure culture of LC705.  
 
 
4.3.5. Gut wellbeing measured as defecation frequency (Study III and IV) 
 
A slight increase in defecation frequency during the consumption of the juice containing P.
freudenreichii ssp.shermanii JS and L. rhamnosus LC705 was observed in elderly 
institutionalized persons (Study III) (Table 19). In healthy adults (study IV) the defecation 
frequency showed increased tendency from the baseline to consumption period, but was 






Table 19. The effect of the consumption of L. rhamnosus LC705 and P. freudenreichii 
ssp.shermanii JS on the defecation frequency (average/week ±SD) of the elderly (Study III). 
 
 Baseline Treatment Follow-up 
Control 2.2 ±1.4 1.7 ±0.5 2.2 ±0.4  
LC05+JS 2.1 ±0.9 2.6 ±1.0* 2.3 ±0.8 






5.1. Technological and bioprotective applicability as a combined culture in foods 
 
Alternative, natural techniques for ensuring the high microbiological quality of foods without 
chemical preservatives are of great interest. In this study the technological applicability of the 
strains P. freudenreichii ssp. shermanii JS and L. rhamnosus LC705 as a bioprotective 
culture in fermented milk products (quark and yoghurt) and wheat bread was studied. The 
effective concentration of the bioprotective culture against yeasts and molds was at a level of 
7 log10 CFU g
-1 fermented milk product. Similarly, the culture was active against Bacillus sp. 
in wheat bread at the level of 8 log10 CFU g
-1 sour dough. The concentrations were 
economical and the procedures technologically feasible for the commercial applications. 
However, the efficacy of the antimicrobial activity may be contaminant and product 
dependent and therefore the antimicrobial spectrum cannot be generalized against all yeasts 
or molds causing spoilage in fermented products or against all Bacillus species in cereal 
products. 
 
The combination of P. freudenreichii ssp. shermanii JS with L. rhamnosus LC705 was 
chosen for the bioprotective application study because the preliminary tests indicated that the 
synergistic effects of the strains JS and LC705 were more efficient against wide range of 
yeasts and molds than the effect of these strains alone (Mäyrä-Mäkinen & Suomalainen, 
1995), an observation similar to Miescher Schwenninger & Meile (2004).  
 
The mechanisms and possible compounds behind the animicrobial action of the combination 
JS+LC705 were not studied further. Lactic and propionic acid with other non proteinaceous 
compound such as phenyl-lactic acid (PLA) may play a crucial role in the inhibition. 
Synergistic effects of acetate, lactate and propionate are likely to be important; however, Lind 
et al. (2005) reported that the effect of propionibacteria against certain yeasts and molds was 
not totally explained by acids. Also, bacteriocins may be involved in the bioprotection of 
foods (Holo et al., 2002). P. freudenreichii species are reported to produce bacteriocins 
(Gwiazdowska & Trojanowska, 2006; Warminska-Radyko et al., 2001) and similarly, 
bacteriocin production has been reported for L. hamnosus (Weese, 2002) but as no studies 
for bacteriocin production of P. freudenreichii ssp. shermanii JS or L. rhamnosus LC705 has 






5.2. P. freudenreichii ssp. shermanii JS a as candidate probiotic strain 
 
5.2.1. Biological properties 
 
The current probiotic concept includes that each probiotic strain should have its own 
documentation even though applied in a culture combination. L. rhamnosus LC705 has been 
described for its biological properties otherwise (Tuomola et al., 2000; Mäyrä-Mäkinen et al., 
2002). In this study, P. freudenreichii ssp. shermanii JS was characterized for its applicability 
as a candidate probiotic strain vitro. At the selection phase the assays of safety 
characteristics and the tolerance to upper GI-tract conditions by in vitro tests are prime 
concerns. The excellent tolerance of P. freudenreichii ssp. shermanii JS to conditions 
encountering in upper gastrointestinal tract was shown in vitro for the cells. The cells of the 
strain JS tolerated with high cell numbers acidity until pH 2 in which the conditions caused 
drastic cell death. Bile salts were not affecting the JS strain. The survival of the strain JS is 
comparable with other potential probiotic P. acidipropionici and P. freudenreichii strains 
(Zarate et al., 2000; Huang and Adams, 2004; Herve t al., 2007).  The activity of certain 
bacterial enzymes such as azoreductase, nitroreductase,  β-glucuronidase, and β-glycosidase 
produced by the intestinal microbiota  have been conected to the release of potentially 
carcinogenic compounds in the colon (Rowland, 1992; Chadwick et al., 1992) and therefore 
the enzyme profiles of potential probiotic strains have been characterized. In this study, the 
enzyme activity profiles of the strain JS was studied in vitro with the semiquantitative API 
ZYM system which showed no production of β-glucosidase, similarly as in the study of 
Perez-Chaia et al. (1999) with P. freudenreichii strains CRL 757 and SG1 or P. 
acidipropionici strains Q4 and CRL1198 . The other harmful enzymes of interests are not 
included in API ZYM test assay. Instead, a positive enzyme activity of β-galactosidase was 
detected with high intensity, similarly as evidenced in the study of Zarate et al. (2000) with P. 
freudenreichii and P. acidipropionici. It is suggested that β-galactosidases of PAB may be 
active within the gut (Zarate et al., 2002) and thus elpful in treating lactose intolerance.  
 
Adhesion of the probiotic strain to the intestinal mucosa is considered an important factor  at 
least for the immunomodulatory effects in which theclose contact between the probiotic cells 
and the immunologically active cells is thought to be essential (Brassart & Schiffrin, 1997). 
Thus, in vitro adhesion to human mucus preparation may be an indication of possible in vivo 
adherence ability and it may be associated with the transient colonisation (Johansson et al., 
1993). However, to study the in vivo adherence is demanding as adherence is associated to 
the mucosa-associated cells (Walker et al., 2006) and only invasive techniques such as 
colonyscopy could be used for the sampling of mucosa-associated cells (Alander et al., 1999). 
The colonoscopy demands ethical approval and it is laborious to perform, and therefore the 
use is generally restricted to severe cases. In this study the adherence of the strain JS was 
studied to human resected mucus in vitro and the assay showed a moderate adherence 
compared to the other PAB strains. Interestingly, the adhesion of the other PAB but not of the 
strain JS was enhanced in combination with selected probiotic bacteria, e.g. with well known 
LGG. Despite the in vitro adhesion results, it can be assumed that the strain JS does interact 
with the intestinal mucosa as in an intervention trial with three different bacteria genera, one 
of them being the strain JS, on immunomodulatory capa ity (Kekkonen et al., 2008), all the 





reducing the serum hsCRP level of the healthy adults, thus indicating a potential for anti-
inflammatory effects. Thus, the relevance of in vitro adherence for indicating the biological 
activity is arguable.  
 
5.2.2. Safety related aspects of the strain JS 
 
In European member states, according to EFSA scientific committee (Barlow et al., 2007), 
any strain of microorganism of which the identity is established and assigned to a QPS group 
does not need any for further safety assessment tha that conducted by EFSA. Based on that, 
P. freudenreichii species are freed by EFSA from safety assessment. Similarly, L .rhamnosus 
species are freed by EFSA. 
 
A major area of concern has been the potential for antibiotic-resistance transfer in the 
gastrointestinal tract that might take place between probiotics and pathogenic bacteria 
(Salyers et al., 2004;  Mathur and Singh, 2005). It is accepted that antibiotic resistance is not 
a hazard unless it renders the probiotic untreatable in rare cases of infection or unless it can 
be transferred to potential pathogens. Certain probiotic LAB and BIF cultures seem to carry 
acquired tet(W) gene which mediates ribosomal protection to tetracycline. High Tet(W) 
frequency among the intestinal and oral microbes of humans and animals suggest its 
transferability (Kastner et al., 2006) and that may c use extra safety concerns with these 
certain potential probiotic LAB and BIF cultures. Dairy propionibacteria exhibit a natural 
antibiotic resistance to oxacillin, aminoglycosides, 1st and 2nd generation quinolones, colistin, 
metronidazole and phosphomycin (Madec et al.,1994; Chamba et al.,2007). According to 
MIC distribution data based on VETMIC panel in this study, the P. freudenreichii ssp. 
shermanii strain JS could be regarded susceptible to all other antibiotics, except for 
aminoglycosides (streptomycin, gentamicin and kanamycin), similarly as the other dairy 
PAB. The resistance to aminoglycosides is a common characteristic of anaerobic bacteria as 
they lack a cytochrome-mediated drug transport system (Bryan and Kwan, 1981). No study 
with the JS strain or with other current potential P. freudenreichii probiotics has been 
conducted to clarify if the antibiotic resistance is plasmid or chromosomally coded. The 
assumption lies on the chromosomal resistance genes as no differences in the antibiotic 
resistance patterns were seen between parent and plsmid-cured strains of dairy PAB 
(Rehnberger and Glatz, 1990). Additionally, metionidatzole resistance gene nimA in 
cutaneous PAB was detected in strains without plasmids, suggesting chromosomal location 
(Lubbe et al., 1999). All in all, the genotyping of the antibiotic resistances is recommendable. 
 
5.3. In vivo performance and functionality of the culture combination of P. 
freudenreichii ssp. shermanii JS and L. rhamnosus LC705. 
 
5.3.1. In vivo survival 
 
The preliminary intervention trials indicating in vivo survival pattern and possible probiotic 
traits are needed for the final assessment of the probiotic traits. In this study the probiotic 
traits of the strain JS were explored in a culture combination with L. rhamnosus LC705 
administered in a fruit juice. The human interventio  trials confirmed the in vitro tolerance to 
the upper GI tract conditions of the strains JS and LC705. The strains in administration level 
of 10 log10 CFU d





recovery of 60 to 80% for JS and 40 to 70% for LC705 from feces by conventional 
cultivation assays. Similar levels of fecal recovery have been reported for the JS strain in 
other studies (Myllyluoma et al., 2005;  Kekkonen et al., 2008) and for P. freudenreichii 
strain S141 (Jan et al., 2002; Herve et al., 2007). Also, L. rhamnosus LC705 survival and 
colonization pattern was comparable to other former L. casei –group strains (Saxelin et al., 
1999). It is assumed that probiotics do not colonize the intestine permanently as the abundant 
resident microbiota compete the transient exogenous species (Ouwehand et al., 2006). This 
was seen with the strains JS and LC705 as the cell counts decreased below the detection level 
within two weeks from the end of the consumption. Competitiveness or the activities of the 
strains JS and LC705 within the gut microbiota were not studied, but the changes seen in the 
faecal azoreductase activity in this study, in β-glucosidase activity in the study of Hatakka et 
al. (2008a) and in urinary aflatoxin-B-N7-guanine, biomarker for increased risk of liver 
cancer in young men (El-Nezami et al., 2006) indicate that the strains of the combination may 
be able to compete and cause changes within the resident microbiota.  
 
The efficacy of probiotics is dependent on the strain’s ability to reach elevated population 
levels and to remain alive and biologically active in the gut. Variable daily doses from 6 log10 
CFU to 9 log10 CFU have been recommended (Coeuret et al., 2004), but the generalization is 
not recommended as the dose responses are dependent o  strain and carrier matrix as the 
matrix into which cells are incorporated prior to their consumption plays a crucial role in the 
survival of the strains (Saxelin et al., 2003). Unfortunately, only limited numbers of dose-
response studies of probiotics have been performed, ainly with the probiotic LAB strains 
(reviewed in Lahtinen, 2007). In this study the strains were administered in acidic fruit juices 
with average pH level of pH 3.8. Both strains survived during the shelf life of the product and 
through the GI-tract in adequate numbers reaching the level of 6 log10 CFU in feces. 
According to the current opinion, the live cells recovered from the feces do not explain the 
biological activity in the intestine but they verify the good survival pattern of these strains.  
 
5.3.2. Safety related aspects of the combination 
 
P. freudenreichii ssp. shermanii JS and L. rhamnosus LC705 can be considered as safe for 
human consumption. No harmful side-effects on the institutionalized elderly or healthy adults 
during the intervention studies were reported and in the elderly no mucin degradation was 
observed. Most important, P. freudenreichii and L. rhamnosus species are considered as safe 
by EFSA.   
 
5.3.3. Beneficial health effects measured as gut wellb ing 
 
Gut health can be measured by several end points such as bowel movements and transit time, 
abdominal pains, or changes in the gut microbiota cmposition; however for any of these 
parameters the interpretation is complicated by the large individual variability even within the 
normal range (Aggett et al., 2005). In this study, the gut well being was characterized in 
constipated elderly and in healthy adults by following the defecation frequency. The 
combination P. freudenreichii ssp. shermanii JS and L .rhamnosus LC705 was shown to 
relief the constipation in the elderly (p=0.04) during the consumption period of 2 weeks with 
daily dose of 10 log10 CFU. A statistically insignificant tendency to increase the defecation 





susceptible to functional gastrointestinal symptoms than young adults, and therefore 
constipation is relatively common in elderly (Pitkälä et al., 2007; Tiihonen et al., 2008b).  
Interestingly, both B.longum and B.lactis isolated from the elderly and administered in 
fermented oat drinks normalized the bowel movements of he elderly (p=0.004 and p=0.002, 
respectively) (Pitkälä et al., 2007) and a multistrain combination consisting of Bifidobacteria 
sp. and Lactobacillus sp. increased the frequency of bowel movements in ch ldren with 
functional defecation disorder (p=0.009) (Bekkali et al., 2007). Studies performed on 
symptoms of constipation with L. casei shirota (Koebnick et al., 2003) and with B. infantis 
DN-173 010 (Marteau et al., 2002; Meance & Turchet, 2001) in adults showed decrease in 
colonic transit time. The positive effect of probiotics in gut well being is hypothesized to be 
due to the production of organic acids by the strains resulting in a lowering of pH in the colon 
which in turn enhances the motility and subsequently decreases the transit time in the colon 
(Bekkali et al., 2007). In addition, the composition f colon microbiota influences the 
peristalsis of the colon (Picard et al., 2005) Especially in the elderly the counts of 
bifidobacteria have been reported to decline (Hopkins et al., 2002). Interestingly, certain 
propionibacteria are known to enhance the growth of bifidobacteria and this could be an 
approach to affect the bifidobacteria counts in the elderly and thus increase the amount of 
short chain fatty acids. The softening of the stools by stimulating water and electrolyte 
secretion may improve the gut wellbeing (Bongers et al., 2007). Especially ageing seem to 
affect the consistency of the stools by increasing the fecal dry matter (DM) content (Tiihonen 
et al., 2008b), but no probiotic strain has been repo t d to affect on DM content. 
 
5.3.4. Immunological activity 
 
Healthy intestinal mucosa contains abundant immunoglobulin A (IgA)–secreting cells, which 
are generated from B cells in gut-associated lymphoid tissues (GALT)(Rodrigo Mora et al., 
2006). IgA secreting cells are mainly detected from the saliva or faecal samples. In this study, 
IgA, IgG and IgM were analyzed from the peripheral blood of the healthy adults. It remains 
uncertain whether the observed change in IgA secreting cells is biologically relevant, partly 
because the evaluation of the changes in blood cell immune responses does not explain the 
actual physiological effects (Delcenserie, 2008) and because the subjects were healthy adults 
with no reported side effects. In addition, no changes were seen in the frequency of IgG- or 
IgM secreting cells. The strain JS was not studied for any health promoting activity alone in 
any of these studies, but the study of Kekkonen et al. (2008) gives the indications that the 
strain JS as a single culture may pose a promising anti-inflammatory activity. 
 
5.4. Confirmation of the biochemical identifications 
  
The conventional cultivations of faecal samples are commonly used for the measurement of 
viability of ingested strains. The enumeration of the strain JS from feces was conducted by 
conventional cultivation on PPA medium which is a buffered modification of the traditional 
YEL-medium (yeast extract lactate-medium) with the supplementation of 1 % (w/v) β-
glyserolphospate which was added in order to diminish the acidity stress caused by lactic acid 
bacteria in the faecal samples. A more selective PAL ropiobac® medium can be used 





power of PPA was sufficient (data not shown), PAL Propiobac® medium was not used in this 
study. The identification of P. freudenreichii isolates to the species level was performed by 
23S rDNA restriction analysis and to the strain leve  by RAPD. The RAPD profile consisted 
of 900-, 340-, and 250-bp DNA fragments, of which 340- and 250-bp fragments are typical 
for P. freudenreichii species and the fragment 900-bp typical for the strain JS, only. The 
specificity of RAPD assay was confirmed with PFGE analysis which is the golden standard 
method for the strain identification.  
 
For dairy Propionibacterium species identification, PCR-based methods are available for 
genus and species level (Meile et al., 1999; Tilsala-Timisjärvi and Alatossava, 2001) and for 
the confirmation of the strain identity, methods such as PFGE and RAPD-PCR are available 
(Gautier et al, 1995; Rossi et al., 1998). In this work, strain-specific RADP-PCR was used to 
identify the strain JS in feces and the further identification was confirmed with PFGE. 
Interestingly, the biochemical characteristics of P. freudenreichii species can be used for 
differentiating P. freudenreichii species from other dairy species (Dherbecourt et al, 2006) 
and within the P. freudenreichii subgroups, P. freudenreichii ssp. shermanii types can be 
differentiated from P. freudenreichii ssp. freudenreichii by their nitrate reduction and lactose 
fermentation. In this study, the biochemical identification was true for 94.5% of the 
preliminary isolates confirmed with genomic identification and in a study of P. freudenreichii 
S141, 93% of the preliminary isolates were identified as S141 (Jan et al., 2002).  
 
Conventional cultivation of fecal bacteria gives numbers of live cells but does not indicate 
metabolic activity of cells during the transit in GI tract. Besides, cultivation based methods 
bear several other discrepancies such as inability to detect the dormant or injured cells 
(Anderson et al., 2004). Therefore the relevance of the conventional cultivation of fecal 
samples is discussed. The recent development in quatitative PCR methods is notable, but 
due to the expensive investments needed, they are not commonly accessible. On the other 
hand, DNA-based techniques do not discriminate betwe n living and dead cells and do not 
indicate the metabolic activity of the cells. Therefo  bacterial mRNA has been considered as 
an indicative marker for the cell viability (Sheridan et al., 1998) and metabolic activity 
(Herve et al., 2007). Non-invasive molecular marker based on 5S subunit of transcarboxylase 
has been described for P. freudenreichii species (Herve et al., 2007). This 5S subunit of 
multienzyme complex of transcarboxylase is specific for P. freudenreichii species and as its 
expression occurs only during the propionic acid fermentation indicating the metabolic 
activity of the cells it offers an interesting option for the detection of metabolic activity. 
However, a successful in situ detection of mRNA requires that the cells are permeable to 
reverse transcriptase and RNA polymerase, that amplificon products do not already exist in 
the cells and that mRNA is present in sufficient concentration for its signal to be detectable 
(Walker et al., 2006).  
 
The enumeration of LC705 was conducted on LAMVAB agar (Hartemink et al., 1997) and 
typical LC705 type colonies were selected for genotyping with randomly amplified 
polymorphic DNA (RAPD) with OPA-3 primer. For the confirmation of the genotyping, 
several other primers were used. Half of the subjects in the intervention study had isolates 
with typical colony morphology and with identical RAPD patterns for the strain LC705 
already in the beginning of the study. The discriminatory power of the method is proven 
adequate (Alander et al., 1999), therefore it is assumed that those subjects were consumers of 
products containing the strain LC705 as a technological cheese starter. In this study, no 








This study ensures the role of P. freudenreichii ssp. shermanii JS and L. rhamnosus LC705 as 
candidate probiotics in a combined culture. Besides, the study proves the in vitro probiotic 
potential and safety of P. freudenreichii ssp. shermanii JS and in vivo safety of the combined 
culture.  
 
P. freudenreichii ssp. shermanii JS has been used for decades as a primary cheese starter and 
L. rhamnosus LC705 as an adjunct cheese starter in big eye cheeses in Finland. In this study 
the strains were applied in fermented products (yogurt and quark), in wheat bread, and in fruit 
juices (pH 3.8). The strains survived without any major loss in cell counts through the shelf 
lives of all products. The industrial scale production processes for both strains exist with high 
cell yields. These results and the good technological applicability indicate excellent 
fermentation, downstream processing and stability of the strains JS and LC705 in the 
products.  
 
The studies with the combination of the strains JS and LC705 administered in fruit juices 
monitored primarily the survival of the strains JS and LC705 during the GI transit on healthy 
adults and secondly their effect on gut wellbeing properties measured as relief of constipation 
in institutionalized elderly and in healthy adults. An excellent survival and a transit 
colonization on the GI tract of healthy adults was proven for both strains. Especially the 
recovery rate of 70 to 80% of the JS strain was excellent even though the strain was 
administered in a demanding matrix of a whey-based fruit juice with a low pH of 3.8. An 
improvement in gut wellbeing measured as defecation frequency was reported in the 
institutionalized elderly and a trend of the increas d defecation frequency in healthy adults. 
No side effects were reported in the human intervention trials and in vitro characterization of 
the strain JS ensured the safety by showing no deviation in the antibiotic resistance pattern 
compared to other PAB. Beside the phenotypic antibiotic resistance pattern, the presence of 
antibiotic resistance genes of the genome should be tested in order to confirm that the 
resistance is not plasmid encoded.  
 
The biochemical identifications of the strains from the faecal samples were confirmed with 
modern molecular biological tools. The strain JS was identified to the species level by 
performing 23S rDNA restriction analysis and to the strain level by RAPD profiling. 
Similarly, the strain LC705 was identified to the strain level by RAPD profiling. Thus, strain 
specific identification methods were confirmed during the study. 
 
Separately, the combination of P. freudenreichii ssp. shermanii JS and L. rhamnosus LC705 
was evaluated from the technological point of view as a bioprotective culture and the efficacy 
was proven against common spoilage yeasts in fermented milks and against ropiness causing 
Bacillus sp. in wheat bread. This natural bioprotective activity will be a valuable asset within 
the growing interest for mild food preservation tools.  
 
In conclusion the combined culture of P. freudenreichii ssp. shermanii JS and L. rhamnosus 
LC705 has an encouraging role as a properly identifi d and safe probiotic culture with a 





Moreover the combined culture may have an innovative dual role acting as a bioprotective 
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